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 gene lead to combined pituitary
hormone deficiency (CPHD), which is characterized by a deficiency
of GH, TSH, LH/FSH, PRL and, less frequently, ACTH. This study
was undertaken to investigate the molecular defect in a cohort of
patients with CPHD.
 
Design, patients and measurements
 
A multicentric study involving
46 cases of CPHD (17 familial cases belonging to seven kindreds and
29 sporadic cases) selected on the basis of clinical and hormonal
evidence of GH deficiency, central hypothyroidism and hypogona-
dotrophic hypogonadism, in the absence of an identified cause




 were investigated by DNA
sequencing. Clinical, hormonal and neuroradiological data were






 mutations were identified in all familial cases: five













 T (R120C) mutation and one presented


















 301–302delAG, in both). Phenotypic variability was
observed among patients with the same mutations, particularly the
presence and age of onset of hypocortisolism, the levels of PRL and
the results of pituitary imaging. One patient presented a sellar mass




This is the first report of a mutation in the initiation




 gene and this further expands the spectrum of
known mutations responsible for CPHD. The low mutation fre-
quency observed in sporadic cases may be due to the involvement
of other unidentified acquired or genetic causes.
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 and encodes a 226-amino acid transcription





Mutations in this gene were originally discovered in a mouse




 which is characterized by a
hypoplastic pituitary gland and combined deficiency of GH, TSH









 which has an autosomal recessive
mode of inheritance and is associated with deficiency of LH, FSH,
GH, TSH, PRL and, less frequently, ACTH.
Although patients often present with growth retardation, central
hypothyroidism and hypogonadotrophic hypogonadism, the hor-





illustrated by the observation of some patients who undergo spon-
taneous puberty before developing central hypogonadism and by the




The mechanism underlying the variable expression of the CPHD
phenotype is unknown.
Pituitary size can also vary among patients and, unlike the mouse
model, it is not uncommon to find pituitary masses in affected
children that can be potentially mistaken for craniopharyngiomas,














Table 1) affecting mainly the DNA-binding and transcrip-
tional activation domain of the protein.
We have undertaken studies to uncover the molecular defect in a
large cohort of patients with familial and sporadic CPHD.
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A multicentric study was launched in Portugal to screen for muta-




 gene in patients with CPHD. Endocrinologists
based at national endocrine referral centres, serving the northern,
central and southern regions of the country, were invited to select
patients from their outpatient clinics, over a period of 2 years and
according to predefined selection criteria. Patients were selected on
the basis of clinical and hormonal evidence of GH deficiency, central
hypothyroidism and hypogonadotrophic hypogonadism, in the
absence of an identified cause of hypopituitarism, and classified
according to family history, as familial or sporadic cases.
A total of 46 cases were assessed, 17 belonged to seven apparently
unrelated families with a positive history of CPHD and 29 were sporadic
cases. As the majority of participating centres were adult endocrine
units, only eight patients were under 18 years of age at the time of
this study. All selected patients agreed to be included in the study.
As there was no central registry of CPHD patients, an undetermined
number of patients under the care of nonendocrine specialties may
have been excluded from this study.
Clinical, hormonal and neuroradiological data were collected
from each patient by physicians at each referring centre. The
biochemical study was performed by measuring free T3 and T4,
IGF-1, oestradiol /testosterone and PRL at baseline. As patients
were studied at various centres using different commercial hor-
monal assays, normal values for each centre were taken into
account. Anterior pituitary function was assessed by determining




g, iv), the LH and FSH res-

















g, iv) and the GH, cortisol and ACTH responses to




Onset of ACTH deficiency was considered retrospectively to be the
earliest age at which the stimulated cortisol levels fell below
550 nmol/ l.
Fig. 1 Structure of the PROP1 gene and positions 
of mutations reported so far. The coding region 
is represented by shaded boxes. Introns and 
untranslated regions (UTRs) are not drawn to 
scale. Mutations found in the current study are 
highlighted.
Exon Nucleotide change* Mutation type Predicted effect on protein Ref.†
1 c. 2T → C Initiation codon No translation This study
1‡ c. 109 + 1G → T Splice-donor site Abnormal mRNA splicing 20
2 c. 112–124del 13 bp Deletion/frameshift Truncation at codon 480 21
2 c. 149–150delGA Deletion/frameshift Truncation at codon 109 22
2 c. 150delA Deletion/frameshift Truncation at codon 164 23
2 c. 157delA Deletion/frameshift Truncation at codon 164 24
2 c. 211C → T Missense Amino acid change R71C 25
2 c. 212G → A Missense Amino acid change R71H 25
2 c. 217C → T Missense Amino acid change R73C 1
2 c. 218G → A Missense Amino acid change R73H 26
2 c. 247C → T Nonsense Truncation at codon 83 27
2 c. 263T → C Missense Amino acid change F88S 28
2 c. 295C → T Nonsense Truncation at codon 99 26
2 c. 296G → A Missense Amino acid change R99Q 29
2 c. 301–302delAG Deletion/frameshift Truncation at codon 109 4
3‡ c. 343-2A → T Splice-acceptor site Intron retention/truncation§ 1
3 c. 349T → A Missense Amino acid change F117I 4
3 c. 358C → T Missense Amino acid change R120C 4
3 c. 582G → A Nonsense Truncation at codon 194 30
*Nucleotide +1 corresponds to the A of the ATG translation start codon.
†Only the first literature report is indicated for each mutation.
‡Nearest exon (intronic mutation).
§A smaller percentage of transcripts use an alternative cryptic splice site resulting in a four-codon 
deletion.
Table 1. PROP1 germline mutations so far 
reported in the literature
 PROP1
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Venous blood samples were obtained after informed consent using
guidelines approved by the local research ethics committee and
genomic DNA was extracted using standard methods. Each of the




 gene was amplified by polymerase chain






































 Tris–HCl (pH 9·0). Cycle conditions consisted of initial

















C for 1 min, with a final extension




C for 10 min. The PCR products were purified using the
QIAquick PCR purification kit (Qiagen) and direct sequencing of
both strands of the products was carried out on a CEQ8000 capillary
sequencer using the CEQ Dye Terminator Cycle Sequencing Quick
Start Kit (Beckman Coulter, Fullerton, CA, USA) with the same
PCR primers.
Mutations were confirmed by repeating the PCR followed by the
use of appropriate restriction endonucleases for the nucleotide
changes and gel electrophoresis of the digested fragments. Nomen-





where c indicates the cDNA sequence and XXX represents the altered
nucleotide(s) of that sequence. Previously unreported nucleotide
changes were screened for in a panel of 55 normal individuals (110








 gene were found in all familial




 301–302delAG, was found in five families (F1, F2, F4, F6 and F9)
















 C mutation. All mutations were present in homozygosity.
No other mutations of the coding sequence of the gene were present
in the remaining 27 sporadic cases. Mutations were also confirmed









I that resulted in fragments













I restriction site that
resulted in fragments of 448 and 131 bp, instead of the normal PCR













I that would normally cleave the 326-bp PCR product
into fragments of 197 and 129 bp (Fig. 3).
All 19 patients with germline mutations (Table 2) had presented
with growth retardation and central hypothyroidism during childhood
and complete absence of puberty. GH, TSH and LH/FSH deficiencies
were demonstrated in all of these patients. PRL levels were under
5 ng/ml, in 15 out of 19 cases, and ACTH impairment was present
in eight out of 19 cases, with an age of onset ranging from 11 to 36 years
(Table 2). Magnetic resonance imaging (MRI) scans demonstrated
pituitary hypoplasia or empty sella in all except one patient aged
27 years, who presented a nonenhancing sellar mass with hyper-
intensity in T1 and low signal in T2 (Fig. 4). This mass was initially
detected during a first MRI performed at 16 years of age, and at that

















extension above the sellar fossa. This mass maintained these char-
acteristics up to the age of 21 years (Fig. 4) and then underwent a

















which was present in five out of seven kindreds and in the only two




 germline mutations. This 2-bp deletion
occurs in a dinucleotide repeat mutational hotspot and is the most









 defects. This deletion, which
occurs in exon 2, is predicted to cause a frameshift in the coding
sequence starting at codon 101 with a premature termination at
Fig. 2 Family trees of CPHD patients found to 
harbour PROP1 germline mutations. Individuals 
are represented as males (squares), females 
(circles), affected (filled symbols), unaffected (open 
symbols) and deceased (oblique line through 
symbol). The double line represents a 
consanguineous marriage. Patients F3 II-1 and F8 
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codon 109, leading to the loss of the DNA-binding homeodomain














 358, resulting in the sub-
stitution of an arginine by a cysteine at codon 120, which has been




Our study revealed a novel initiation codon mutation of the
PROP1 gene, which is also the first reported mutation in exon 1 of
this gene. Several examples of mutations in the ATG initiation codon
and in the flanking consensus sequence have been reported in associa-
tion with human disease.11 Unlike some other organisms, eukaryotic
ribosomes rarely initiate translation at a codon other than ATG.12
For some genes, elimination of the initiation codon can result in the
use of an alternative downstream ATG codon as the translational
initiation site. There are no ATG triplets upstream of the normal
initiation site in the PROP1 cDNA deposited in GenBank (accession
NM_006261) and there are only two that are located downstream
within the coding region. The first is located at nucleotides
c. 518–520 but is out of frame. The second is located at nucleotides
c. 640–642 and is in frame, but lacks the flanking consensus
sequence, and even if translation occurred, the resultant peptide
would only have the terminal 13 residues instead of the normal 226
amino acids that constitute the fully translated protein. The encoun-
tered mutation therefore appears to lead to a null allele that abolishes
the translation of the PROP1 protein.
All patients with these mutations had deficiency of GH, TSH and
LH/FSH; however, there was phenotypic variability in terms of the
levels of PRL and the presence of ACTH deficiency, even among
patients with the same mutation. Low levels of PRL were found in
the majority of patients. Although PRL deficiency has been reported
to be variable in several studies, it has not been given as much
emphasis as other hormone deficiencies. This may be due to the lack
of an appropriate definition of this deficiency and to the apparent
lack of clinical consequences, with perhaps the exception of puer-
peral alactogenesis following successful fertility treatment.13 In the
Ames mouse, PRL was not detectable by immunoprecipitation14 but
PRL-immunoreactive cells could be identified,15 so it is conceivable
that in humans some residual function may occur. ACTH impairment
has been increasingly recognized as a late-onset complication in
Fig. 3 Identification of a novel initiation codon mutation. (a) Partial 
sequencing data of the wild-type and mutant alleles in family F5 showing a 
T to C transition of the second base of the methionine initiation codon 
(arrow). This c. 2T → C mutation was present in homozygosity in the 
affected family members. (b) Digestion of PCR amplified fragments with 
NcoI demonstrating loss of the corresponding restriction site in both patients 
(II-3 and II-6) from family F5. In unaffected control individuals (N1–N3 
shown), the presence of the NcoI restriction site leads to cleavage of the 
326-bp PCR product into fragments of 197 and 129 bp. DNA size markers 
(m; 100-bp ladder) are indicated.
Fig. 4 MRI of the sella turcica in a woman with CPHD (patient F6 II-8, 
Fig. 2 and Table 2) caused by a homozygous PROP1 gene mutation 
(c. 301–302delAG). (a) Midsagittal T1-weighted scan at 21 years of age, 
showing a space occupying lesion (arrow). This lesion was nonenhancing 
with hyperintensity in T1 and low signal in T2 and measured 
10 × 10 × 12 mm (height × length × width), with suprasellar extension. 
(b) Midsagittal T1-weighted scan at 27 years of age, showing regression of 
lesion (arrow). This lesion maintained the same signal characteristics as 
before, but was smaller in size, measuring 5 × 5 × 7 mm. A 1 cm graded scale 
is shown on the right of the images.
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patients with PROP1 mutations. A previous study of 10 patients with
the c. 301–302delAG mutation showed that five out of six patients
who were over 40 years of age developed ACTH deficiency compared
to only one out of four patients below the age of 40.16 Several of our
oldest patients (up to the age of 66 years) have not developed this
deficiency whereas others presented abnormal cortisol responses as
early as 11 years of age. The cause of ACTH deficiency, which does
not occur in the Ames mouse model, is currently unknown but may
indicate a possible role of PROP1 in the differentiation and/or main-
tenance of corticotroph cells. In agreement with previous reports,17
none of our patients with the mutation c. 358C → T presented this
deficiency and this may be related to some degree of residual activity
conferred by this missense mutation.4
Pituitary size was also variable among patients. MRI demonstrated
pituitary hypoplasia or empty sellae in all patients except one, who
presented an enlarged sellar mass. Pituitary enlargement has been
frequently observed in young patients with PROP1 mutations, but
this feature appears to be followed by degeneration and regression
of the mass, often resulting in an empty sella with a small remainder
of pituitary tissue.6,7 These pituitary masses, with one exception,18
have only been reported in young children and this contrasts with
the MRI results that one of our patients maintained up to the age
of 21 years. In the remaining patients, because of the lack of adequate
imaging studies in childhood, it was not possible to confirm the
previous existence of any pituitary mass, although this would be
compatible with the high frequency of empty sella currently
observed in this group of patients.
Genotype–phenotype correlations were not established because of
the limited number of patients in each mutation group. However,
the phenotype associated with the novel initiation codon mutation
does not appear to differ from that conferred by the more frequent
2-bp deletion.
Only a small proportion (6·9%) of sporadic cases was found to
harbour PROP1 mutations. The majority of cases are thus likely to
be phenocopies resulting from unrecognized acquired causes. Other
genes responsible for CPHD, such as PIT1 and HESX1, were not
analysed in this study as they are normally associated with a different
phenotype, but mutations of other transcription factors such as
LHX3 or LHX4 or other unknown genetic defects cannot be excluded
in these patients.19
Given the mode of inheritance of autosomal recessive disorders,
most patients with mutations would not be expected to present any
family history of the disorder, as each sibling has only a 25% pro-
bability of being affected. In this study, the relatively low ratio of
mutated sporadic to familial cases suggests a possible selection bias
for familial cases at the referring centres, although this would not
alter the main conclusions of the study.
Testing for PROP1 mutations in CPHD patients, even in sporadic
cases, may be warranted in view of the implications in their clinical
management, such as early awareness of the failure to enter spontaneous
puberty, of the risk of future ACTH deficiency and of the natural
history of any existing sellar mass.
In conclusion, in this study of a cohort of CPHD patients due to
PROP1 mutations, we observed variable expression of PRL and ACTH
levels and an unusual case of persistence of a sellar mass into adulthood.
Furthermore, we identified the first mutation in the initiation codon
of the PROP1 gene and this further expands the spectrum of known
mutations responsible for hypopituitarism.
Table 2. Summary of patient phenotypes and mutations
Patient* Mutation
Age† 




(age of onset in years) Sella turcica MRI
F1 II-1 c. 301–302delAG 40 ↓ ↓ ↓ < 1 ↓ (17) hypo
F1 II-2 c. 301–302delAG 35 ↓ ↓ ↓ 5·0 ↓ (11) hypo
F2 II-1 c. 301–302delAG 37 ↓ ↓ ↓ 3·0 N hypo
F2 II-3 c. 301–302delAG 35 ↓ ↓ ↓ 11·0 N hypo
F2 II-4 c. 301–302delAG 30 ↓ ↓ ↓ 2·6 N hypo
F3 II-1 c. 301–302delAG 64 ↓ ↓ ↓ < 1 N hypo
F4 II-2 c. 301–302delAG 49 ↓ ↓ ↓ < 1 ↓ (36) ES
F4 II-3 c. 301–302delAG 44 ↓ ↓ ↓ 3·8 N ES
F5 II-3 c. 2T → C 42 ↓ ↓ ↓ 3·2 ↓ (30) hypo
F5 II-6 c. 2T → C 30 ↓ ↓ ↓ < 1 ↓ (19) hypo
F6 II-5 c. 301–302delAG 33 ↓ ↓ ↓ 2·0 N hypo
F6 II-8 c. 301–302delAG 27 ↓ ↓ ↓ 2·0 ↓ (17) mass
F7 II-1 c. 358C → T 66 ↓ ↓ ↓ < 1 N ES
F7 II-2 c. 358C → T 60 ↓ ↓ ↓ 1·6 N ES
F7 II-3 c. 358C → T 57 ↓ ↓ ↓ 3·6 N hypo
F8 II-1 c. 301–302delAG 18 ↓ ↓ ↓ 8·9 ↓ (17) hypo
F9 II-1 c. 301–302delAG 37 ↓ ↓ ↓ 1·5 ↓ (14) hypo
F9 II-2 c. 301–302delAG 33 ↓ ↓ ↓ 2·1 N hypo
F9 II-3 c. 301–302delAG 29 ↓ ↓ ↓ 6·4 N hypo
*Identification indicates family number and position in pedigree (Fig. 2).
†Age at time of study.
N, normal; ↓, deficiency; MRI, magnetic resonance imaging; hypo, pituitary hypoplasia; ES, empty sella.
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